Cocrystal Pharma (COCP) Long-Term Deferred Tax (2015 - 2020)

Cocrystal Pharma (COCP) has 6 years of Long-Term Deferred Tax data on file, last reported at $17.2 million in Q4 2020.

• For the quarter ending Q4 2020, Long-Term Deferred Tax rose 11.9% year-over-year to $17.2 million; the trailing twelve-month figure through Dec 2020 stood at $17.2 million (up 11.9% YoY), and the FY2020 full-year result was $17.2 million, up 11.9% from the prior year.
• Long-Term Deferred Tax advanced to $17.2 million in Q4 2020, from $15.4 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $23.9 million in Q4 2016 to a low of $1.5 million in Q3 2018.
• A 5-year average of $15.0 million and a median of $16.1 million in 2018 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax soared 67.53% in 2016 and slumped 37.26% in 2017, its largest moves.
• Tracing COCP's Long-Term Deferred Tax over 5 years: stood at $23.9 million in 2016, then tumbled by 37.26% to $15.0 million in 2017, then gained by 12.3% to $16.8 million in 2018, then fell by 8.56% to $15.4 million in 2019, then gained by 11.9% to $17.2 million in 2020.
• Business Quant data shows COCP's Long-Term Deferred Tax at $17.2 million in Q4 2020, $15.4 million in Q4 2019, and $16.8 million in Q4 2018.